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1. Introduction
Mechanical circulatory support (MCS) has become an essential part of the treatment strategy
for patients suffering acute, reversible ventricular dysfunction or end-stage heart failure.
Cardiac function and systemic blood flow monitoring in patients on ventricular assist device
(VAD) is essential in order to avoid low output syndrome, which remains one of the leading
causes of death after MCS.
Echocardiography is considered as the procedure of choice for the evaluation of cardiac
performance and to gather other critical information both in the pre, intra and postoperative
phases. Also, echo-Doppler-based methods can be used to calculate the flow velocity and
volume and hence systemic blood flow. Unfortunately, due to intrinsic nature, echocardiog‐
raphy cannot be considered a bedside continuous monitoring system.
Several methods are now available for blood flow assessment and cardiac output (CO)
monitoring. An ideal hemodynamic monitoring system should comprise all the key factors
listed in Table 1. However, such a system does not currently exist. Indeed, the ultrasonic
flowmetry from the graft’s outflow is considered as the gold standard method; however, its
use is limited to the intraoperative period. The thermodilution continuous CO method is
increasingly used. However, it incorporates a thermal coil integrated into the pulmonary artery
catheter and it cannot be used in right VAD (RVAD) patients. Pulse contour methods derive
systemic blood flow from the analysis of the arterial pressure waveform. They provide a fast
response time and may represent suitable tools to assess CO and other hemodynamic variables
in patients on MCS.
© 2013 Scolletta et al.; licensee InTech. This is an open access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits
unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
This chapter will review the most commonly used techniques to assess cardiac function and
systemic blood flow in patients assisted with MCS.
1.1. Classification of MCS
Current devices for mechanical circulatory assistance provide a wide spectrum of support,
ranging from short-term to intermediate and long-term duration [1,2], and the current
indications for ventricular assist device implantation are: bridge to cardiac transplantation,
bridge to recovery or destination therapy for patient not candidate to heart transplantation.
For these different purposes, different types of devices able to provide pulsatile or continuous
blood flow are available for clinical use, and selection of MCS device mainly depends by the
degree of the support required, the estimated duration of assistance, the invasiveness of the
implantation procedure and the patient’s need for postoperative mobility [3].
Over the years, three devices generations have succeeded and the rationale of the innovations
and modifications has been mainly focused on decreasing the rate of complications, being the
main determinant for patient outcome (chiefly thromboembolisms, bleeding, mechanical
failure and infections).
1.1.1. First-generation devices
The first generation devices (Thoratec paracorporeal ventricular assist device and Abiomed
BVS 5000) were largely used for bridge to transplant or bridge to recovery. They were able to
provide pulsatile flow by means of large paracorporeal consoles but were associated with high
mortality and complication rates [4,5]. Nevertheless when used for patients as bridge to
transplantation, survival to transplant improved and resulted in optimizing patients’ overall
hemodynamic status allowing them to be better surgical candidates [6].
1.1.2. Second-generation ventricular assist devices
The second-generation of devices (HeartMate IP/XVE, Novacorand Arrow Lionheart) also
provided pulsatile flow but were implanted as intra-corporeal pumps allowing greater patient
mobility and resulting in reduced complications and infection rates compared to first-
generation devices [3].
1.1.3. Third-generation ventricular assist devices
The concept and the goal of destination therapy guided the development of third-generation
VADs (HeartMate II, Berlin Incor, MicroMed Debakey and Jarvik 2000) [3].
The clinical objectives of destination therapy VADs are to restore an adequate blood flow,
preserving end-organ function and providing significant decompression of failing ventricle [7]
virtually restoring a normal resting hemodynamics, exercise tolerance and normalizing
metabolic as well as neuro-humoral functions [2].
Such devices are currently used and explored in clinical practice. They are fully implantable
axial flow pumps, with design modifications (i.e., lack of percutaneous lines and implantation
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within the pericardium avoiding the need for a pump pocket) that will decrease patient’s
complications [8].
1.2. Hemodynamic principles of VADs functioning: Basic concepts
VADs consist of electromechanical pumps usually placed in parallel with the native patient’s
circulation. Their principal components consist in:
1. Inflow cannula. Direct the blood from one of the heart chambers to the device. Typically,
for a LVAD, the inflow cannula originates in the left atrium (LA) or left ventricle (LV). For
a RVAD, the inflow cannula originates in the right atrium (RA) or right ventricle (RV).
2. Pump. Provides propulsion to the blood. The generated flow can be either pulsatile
(pneumatically or electromechanically driven pumps, e.g., Abiomed BVS 5000, HeartMate
I, Novacor, Thoratec), or continuous such as in the most recent axial-flow devices
(HeartMate II, Jarvik 2000, MicroMed DeBakey, Berlin Incor Heart) [9-11] or centrifugal
pumps (Biomedicus, Levitronix-Centrimag and TandemHeart) [12,13]. Because of the
larger size, the requirement of unidirectional valves in the VAD inflow and outflow
cannulas, and complicated control mechanism of pulsatile VADs, axial flow pumps have
been gaining popularity [11]. In non-pulsatile axial-flow pumps, the propulsion principle
is based on a rotating impeller pump, which ejects blood to the systemic circulation at a
fixed rate depending on pump speed and inflow–outflow pressure gradient. The advan‐
tages of these systems are that they are smaller, do not require unidirectional valves, are
more durable, and typically generate higher flows at lower pressures.
3. Outflow cannula. The outflow cannula returns the blood to the patient. The LVAD outflow
cannula is usually anastomosed to the ascending aorta (or descending aorta with Jarvik
2000) and to the main pulmonary artery (PA) in RVAD.
4. Controller. The controller operates the pump by receiving and processing information
from it.
Different devices and controllers range from paracorporeal VADs with transcutaneous inflow
and outflow cannulas or intracorporeal VADs with transcutaneous drivelines, to completely
implantable intra- or extra-ventricular systems. The VAD performance characteristics produce
distinctive relationships between pressure and flow in the circulation. These will determine
measured hemodynamic parameters as well as echocardiographic signals (such as the
continuous (CW) and pulsed wave (PW) Doppler signals) [5,14].
2. Echocardiography in patients assisted with VAD
Since low-output syndrome with impaired tissue perfusion and organ dysfunction still
remains the main cause of death in such patients [15,16], the determination of both left
ventricular function and CO is a decisive and mandatory issue in all the patients implanted
with VAD. Echocardiography is the principal tool to investigate the LV function whereas
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different methods are available for CO estimation. Nonetheless, because of changes in
hemodynamic and blood flow physiology related to every single device, the type of generated
blood flow (pump type) and the position of cannulas and pump, respect to native patient’s
circulation, make the evaluation of CO and ventricular function a challenging issue.
2.1. Echocardiographic examination
Echocardiography is  an important tool  in the management of  patients undergoing VAD
implantation, since it can easily provide critical information about pre-operative anatom‐
ic  abnormalities,  guide  the  device  implantation  procedure,  and  evaluate  post-insertion
cardiac  and  device  function.  Combined  information  from  both  transthoracic  (TTE)  and
transesophageal  (TEE)  echocardiography are  used pre,  intra  and postoperatively  to  this
purpose [17].
Echocardiographic assessment of patients undergoing VAD insertion involves aspects
pertaining both to a general echocardiographic examination and to specific considerations
associated with the VAD. The variety of VAD models with different basic and operational
principles actually impose specific echocardiographic assessment targeted to the characteris‐
tics of the implanted device. This makes essential that the sonographer have a clear under‐
standing of the specific device characteristics to perform a suitable examination. In addition
to the standard assessment, essential device-specific considerations in the echocardiographic
evaluation include:
a. pre-VAD examination. This includes the analysis of the heart and large vessels to exclude
significant abnormalities, such as aortic regurgitation, tricuspid regurgitation, mitral
stenosis, pulmonic regurgitation, patent foramen ovale, or other pathologies leading to
right-to-left shunt after LVAD insertion. Moreover, intracardiac thrombi, ventricular
scars, pulmonary hypertension, pulmonary embolism, and atherosclerotic disease in the
ascending aorta can be easily detected by TTE.
b. intra- and post-VAD examination. The examination includes the device function evaluation
and reassessment of the heart and large vessels. The examination of the device is focused
to confirm the effective device and heart deairing, the cannulas or device alignment and
patency, and competency of device valves using two-dimensional, color, continuous and
pulsed wave Doppler modalities. Heart reassessment must provide information to
exclude aortic regurgitation and intracardiac right-to-left shunt, as well as to assess the
RV function, LV unloading, and the effect of device settings respect to global heart
function.
2.2. Defects creating intracardiac shunts
2.2.1. Patent Foramen Ovale(PFO) and other abnormalities of interatrial septum
The presence of PFO must be always ascertained before and after cardiopulmonary bypass
(CPB). Because of increased LA pressure with rightward deviation of the interatrial septum in
patients with LV failure, investigation of a PFO with color-Doppler echocardiography in the
Recent Advances in the Field of Ventricular Assist Devices26
pre-CPB period can be easily performed (demonstrating a left-to-right shunt). Conversely a
bubble study may not reveal a PFO due to the difficulty in producing a reversal of the left-to-
right atrial pressure gradient in the presence of left heart failure. Likewise, in the case of
biventricular failure, increased RA and LA pressures reduce the interatrial pressure gradient,
hindering PFO detection by both agitated saline and color-Doppler. It must be always kept in
mind that patients without a detected PFO in the pre-CPB examination can present it once
LVAD becomes operating, because the LV unloading and decreased LA pressure associated
with maintained/increased right heart pressures, may open an unsealed PFO. Those hemo‐
dynamic conditions can favour a paradoxical embolism. Because the presence of right-to left
shunt can result in the development of severe hypoxemia (with the degree of shunting also
aggravated by chest closure resulting in RA pressure increase), significant right-to-left
shunting should always be assessed with TEE as early as possible and also during the weaning
from CPB, because a PFO can be potentially detected even before complete separation. Early
detection is fundamental because the presence of a PFO requires return to CPB for closure.
2.2.2. Valvular and ascending aortic defects
2.2.2.1. Aortic valve opening and function
Because of the increased aortic-LV pressure gradient the aortic valve (native or prosthetic)
usually remain closed throughout the whole cardiac cycle during full LVAD assistance. This
is typical for pulsatile VADs generating full CO. Conversely, in VADs providing partial or
intermittent unloading (e.g., Jarvik 2000, HeartMate II) [18] a transient opening of the aortic
valve might be detected. In such devices the intermittent opening of the aortic valve is a target
for device setting (e.g., opening of the aortic valve documented echocardiographically once
every three cardiac cycles for a HeartMate II and reduction of pump output in the Jarvik 2000
to allow for ventricular ejection through the aortic valve) [5]. In these cases M-mode imaging
is used to assess the duration of aortic valve opening [5]. In some particular devices, such as
the Impella (that is placed in trans-aortic position) TEE examination is fundamental for its
correct positioning.
The identification of aortic regurgitation (AR) (either pre- or postoperative) is essential in
patients implanted with a LVAD. Indeed, AR may reduce the forward stroke volume gener‐
ated by the LVAD as a consequence of a blood back-flow (LVAD ejected blood) into the LV.
However, some aspects make the pre-operative echocardiographic evaluation of AR challeng‐
ing in patients suffering severe heart failure because the combination of increased LV end-
diastolic pressure and low aortic diastolic pressure (lowered transvalvular gradient) may
underestimate the degree of AR [19]. The actual rate of late AR (not pre-existent to LVAD
implantation) is relatively low and some recognized factors may contribute to its development
during LVAD support, such as the presence of a closed native valve exposed to systolic
pressure (rather than diastolic) [20], and VAD cannula in the ascending aorta determining
valve distortion.
Other mechanisms of late AR include endocarditis [21], aortic dissection [22,23], and aortic
leaflet prolapse or perforation.
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Nevertheless the presence of severe or moderate AR usually mandate the surgical correction
[24] consisting alternatively in simple leaflets closure (patients requiring long-term support,
bridge to transplantation) which may prevent from systemic embolization also [19,25] or aortic
valve replacement/repair (patients candidate to short-term support, bridge to recovery).
Differently from AR, aortic stenosis (AS) does not determine particular problems in patients
receiving a LVAD because the systemic blood flow is mainly dependent from the pump output
respect to residual ventricular ejection. This is particular true for pulsatile LVADs that are able
to provide a full cardiac unloading. However in the case of VADs providing a partial or
intermittent ventricular unloading (axial flow devices, with intermittent aortic valve opening)
the presence of AS could conversely affect the total systemic blood flow. For this reason patient
with pre-existent AS are not considered as the ideal candidates for such kind of devices. As
for AR the development of aortic stenosis after LVAD implantation, particularly in long term
support with pulsatile devices can result from commissural fusion [26], progressive throm‐
bosis of the aortic valve [27] (due to blood stagnation, low level of anticoagulation, limited/
absent aortic valve movement during LVAD function).
2.2.2.2. Ascending aorta
Pre and intraoperative examination of the ascending aorta is mandatory in patients receiving
a LVAD since it must detect calcifications, atherosclerotic plaques or any other abnormality of
the vessel in the site of anastomosis of the outflow cannula. Depending from VAD’s outflow
cannula placement site the descending aorta should be assessed with the same goal (e.g.,Jarvik
2000). Atherosclerotic plaques of ≥5 mm and/or protruding and/or mobile components are
associated with increased risk of cerebral embolic events.
2.2.2.3. Tricuspid regurgitation
Tricuspid Regurgitation (TR) is common in patients affected by heart failure [28]. However
the presence of an adequate RV function (to maintain an adequate blood flow to the left heart
for LVAD filling) is the key of success in patients receiving a LVAD. In this scenario a significant
postoperative TR can negatively affect the RV function with possible development of a low
output syndrome.
Echocardiographic evaluation of the tricuspid valve (TV) is affected by RV contractility,
preload and afterload of RA, preload and afterload of RV.
Ventricular enlargement, due to preload and afterload increase, contributes to the develop‐
ment of tricuspid regurgitation (annulus dilation and chordal tension) [20,29]. The reduction
of right ventricle preload (pulmonary artery pressure) in patient on LVAD actually does not
determine a reduction of post-operative TR which can, conversely and most frequently, worsen
after implantation.
Different factors and mechanisms are responsible for acute worsening of TR, such as increased
RV preload due to an increased left-sided output delivered by a functioning, increased PA
pressure and RV dysfunction due to the inflammatory response to surgery, CPB and blood
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transfusion, and leftward shift of the interventricular septum produced by the LVAD unload‐
ing and favoured by hypovolemia and high VAD flows.
The influence of LVAD settings on the degree of TR by shifting the interventricular septum
can be frequently observed in axial flow devices where excessively high flow settings exacer‐
bate TR, presumably by mechanisms such as distraction of the septal papillary muscle with
systolic restriction of septal leaflet motion and distortion of the tricuspid annulus. Relative RV
overload and increased PA pressures can further contribute to worsened TR.
Echocardiography must guide the diagnosis of TR and determine the functional cause and
mechanism which, once identified, should be minimized by adjusting the pump setting (flow
reduction flow) in order to reduce the degree of regurgitation and consequently improve RV
function.
2.2.2.4. Mitral regurgitation / stenosis
Mitral Regurgitation (MR) in end-stage heart failure and cardiomyopathy is common [28,30]
and it mostly consists in a functional pathology due to an incomplete leaflet coaptation
secondary to a negative remodeling of both the LV (increased sphericity and dilation, apical
displacement of the papillary muscles with typical valve tethering) and mitral annulus
(increased intertrigonal and anterior-posterion annular size).
The reduction of LV size after LVAD implantation, differently from TR, almost always
contributes to ameliorate mitral leaflets coaptation and, thus, to reduce the degree of pre-
exixtent regurgitation. For this reason, the finding of MR pre-VAD rarely indicates surgical
correction.
Conversely, the persistence of significant MR may indicate suboptimal ventricular unloading
during LVAD support. During VAD support with pulsatile devices MR can, however,
contribute to patient’s symptoms and, in some instances, indicate the surgical correction.
Actually the asynchronous pulsation of the VAD and the assisted ventricle can determine/
worsen mitral regurgitation when LV contraction occurs against both the closed aortic and the
inflow VAD valve.
A low output syndrome during LVAD assistance can result from the presence of mitral stenosis
(MS) resulting in reduced pump filling. Moreover chronic MS associated with pulmonary
hypertension can contribute to postoperative RV dysfunction. Thus, the presence of MS should
be always evaluated in the planning of LVAD insertion and critical MS surgically treated at
the same time.
2.2.2.5. Pulmonic valve
Although rare, the presence of pulmonary valve lesions may have important consequences on
the RV function and output. Critical pulmonic stenosis (PS) in patients under LVADs can
determine an important pressure overload in the RV, compromising the RV output both
directly and indirectly by contributing to RV failure. With regard to pulmonic insufficiency
(PI) apply the same considerations given for aortic regurgitation in the case of RVAD (reduced
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forward flow) while in patients under LVAD the presence of PI (moderate or greater) may
contribute to RV overload/dilatation and possible TR determining a dysfunction of the RV.
2.3. Ventricular assessment
2.3.1. Right ventricle
LVAD assistance can result in two possible and opposite effects on the RV function. The
afterload reduction caused by the left-sided pump may positively increase the function of the
right ventricle. Opposite, the contemporary augmented left output resulting in increased
preload for the right heart sections can be detrimental in the presence of a compromised RV
function which can rapidly decompensate [31]. The leftward septal shifts also favour RV
dysfunction by reducing RV global contractility [32,33]. Nevertheless, because the LVAD
output is strictly dependent on preload, a sufficient RV function must be warranted to avoid
a low output syndrome due to LVAD low flow.
As a result, the evaluation of pre-implant RV function and early post-operative detection of
severe RV dysfunction (ranging from 9% to 33 in different series) play a key role for the success
of LVAD assistance and patient’s outcome because in the presence of severe RV failure
placement of RVAD may be required and the earlier the detection and the RVAD insertion the
better the outcome [34].
Despite a strong association between preoperative impaired RV function (low PA pressure,
RV stroke work index) and need for RVAD placement has been demonstrated [35,36] RV
failure following LVAD implantation in single patients still remains hard to be predicted
because of the multiple factors potentially contributing to its development [35]. A thorough
pre-operative evaluation of RV function and identification of any predictors for RV dysfunc‐
tion is fundamental to select the patient’s optimal device and to schedule each one for uni- or
bi-ventricular support [35].
Echocardiography is a fundamental diagnostic tool to this purpose. Two-dimensional evalu‐
ation of the RV function and dimensions is made by analysing RV inflow–outflow in mid-
esophageal (ME) view and the four-chamber views at transgastric level. This allows the
assessment of both the longitudinal function (RV base-apex motion and free-wall motion) [37].
Quantitative measurements (global RV fractional area change [14,38], regional fractional area
change [33], and the maximum derivative of the RV pressure (dP/dt max)) can be also used to
detail the systolic function of the RV [39,40]. Analysis of tricuspid valve inflow profile is used
for the assessment of diastolic dysfunction. Possible predictors of RV dysfunction after LVAD
implantation are preoperative RV dilatation and increased preload and afterload, and RV
fractional area change < 20%.
2.3.2. Left ventricle
Patients candidate to VAD insertion show a depressed LV function with a LV ejection fraction
(LVEF) usually < 25%. The presence of severe LV dysfunction, particularly if associated with
aneurismal apical dilatation increases the risk of apical clot formation. Pre-insertion evaluation
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of the presence of thrombus in the site of inflow cannula/pump (Jarvik 2000) insertion is a
crucial and mandatory issue of the echocardiographic examination.
Depending by the leading cause of heart failure, the ventricle dimensions and volumes can be
normal or, more often, augmented.
Once on LVAD assistance, the ventricular unloading usually associates with a normalization
of ventricular dimensions and volumes and complete unloading associates with no residual
ventricular ejection and persistent closure of the aortic valve.
Echocardiographic “signs” of LVAD malfunction to be considered are spontaneous contrast
in the LA or LV. Another important feature to be evaluated is the aspect of the interventricular
septum (IVS) because a not adequately unloaded ventricle will show a rightward IVS deviation
suggesting a possible insufficient pump output (due to pump failure, cannulas obstruction, or
other causes).
Leftward IVS shift usually seen with rotary LVAD will, conversely, suggest an excessive
ventricular decompression, which may associate to low pump output as well. Such event can
be due to elevated pump speed, in an axial VAD, RV dysfunction or hypovolemia.
It is important to outline that because of ventricular unloading, the correct evaluation of
systolic function is critical and not easy to be ascertained while on VAD assistance. Several
echocardiographic indexes as well as hemodynamic measurements are used in clinical practice
when patients are scheduled for possible weaning from VAD assistance (see text).
More recently the speckle tracking echocardiography has emerged as a new technique for
the evaluation of myocardial function. This sophisticated method allows the analysis of lon‐
gitudinal, radial and circumferential myocardial deformation (strain) providing a in-depth
evaluation of both global and regional myocardial contractility. Moreover, speckle tracking
echocardiography allows the evaluation of rotational and torsional dynamics of left ventri‐
cle function that only with magnetic resonance imaging (MRI) could be otherwise assessed.
2.4. Assessment of VAD components
2.4.1. VAD cannulas
VAD cannulas are made of woven polyester fabric having hyperechoic density in the echo‐
cardiographic imaging. Depending on single device characteristics, alternative cannulation
methods are used leading to distinct echocardiographic images and considerations.
2.4.1.1. Inflow cannula (Jarvik 2000-pump)
The inflow cannulas correct positioning can be easily visualized on two-dimensional echocar‐
diography although the precise three-dimensional visualization needs to alternative views
(ME four-chamber for deviations towards the interventricular septum, ME two-chamber long-
axis view to assess the anterior–posterior direction). In LVAD they can be placed either in LA
or LV apex. When positioned in the apex it is important to verify that it is correctly aligned
with the left ventricle inflow tract, facing the mitral valve opening without touching any wall
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of the ventricle. Colour-Doppler is a useful adjunct, since an accurately positioned cannula
will show a unidirectional/laminar flow directed to the device, while the finding of turbulent
flow will suggest a not appropriate placement or obstruction of the cannula (thrombosis or
partial obstruction of the cannula by the ventricular wall). Device stroke volume and total
blood flow can be evaluated by PW Doppler measurements obtained from both the inflow and
outflow cannulas. By evaluating the RV and LV outflow tracts, flows PW Doppler can give
also an estimation of eventual residual ventricular ejection in VADs providing only partial
circulatory support.
2.4.1.2. Outflow cannula
In the most of the cases the ouflow cannula of LVADs is anastomosed, as an end-to-side
anastomosis, in the right anterolateral portion of the ascending aorta. Other type of devices,
(e.g., Jarvik 2000), may have the outflow cannula anastomosed either to the ascending aorta
or to the descending thoracic aorta. A long axis view of the ascending aorta will usually show
the outflow cannula anastomosis to the ascending aorta. In the case of RVAD the outflow
cannula is usually positioned in the main pulmonary artery trunk (directly, or inserted through
an incision in the RV apex) although the right PA the can be alternatively used. It can be easily
visualized by two-dimensional echocardiography with a mid-esophageal 20–70° view. The
flow patterns of the outflow cannulas can be evaluated with color-PW and CW-Doppler.
2.4.1.3. Devices with alternative principles and implantation techniques (Jarvik 2000)
Because new devices with alternative principles and cannulation methods have been intro‐
duced in the clinical practice particular echocardiographic evaluations and considerations are
required.
Axial flow pumps offers a number of advantages respect to pulsatilepumps. They are relatively
easy to be implanted (also without the use of CPB), they are smaller (producing a continuous
unidirectional blood flow no valve are needed and do not require a compliance chamber for
systolic-diastolic phases) and suitable for a wide size-range of patients and have lower rates
of complications.
The Jarvik 2000 is an axial flow-based device implanted in the apex of the LV. Because it has
no inflow cannula but the pump itself is positioned inside the left ventricle the TEE examination
is important during and after implantation of this type of device.
It is mandatory that the sonographer is able to guide the precise coring position centred at the
apex and, once implanted inside the ventricle, verify that the pump is perfect in axial alignment
with the mitral valve.
Because no integrated flow sensors are available, echocardiographic evaluation is critical to
assess the device performance and the global hemodynamic. Thus, after Jarvik200 implanta‐
tion the degree of ventricular assistance/unloading (to achieve a full or partial assistance) must
be evaluated by first establishing the speed range at which the aortic valve does not open
(complete unloading). Then by progressively reducing the pump rotationsper minute (usually
1000 rpm steps) it must be assessed the speed at which the aortic valve opens.
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Because outflow cannula of Jarvik 2000 is conventionally anastomosed (trans-pericardial) to
the descending aorta flow patterns proximal and distal to the anastomotic site are quite
different respect to VADs whose outflow cannula is placed in the ascending aorta. Particularly,
at high device flows, which determine a complete unloading with permanent closure of the
aortic valve, stagnation of blood in the ascending aorta and sinuses of Valsalva might occur
with possible thrombosis and obstruction of the coronary ostia with detrimental consequences.
This risk must be reduced or eliminated with the intermittent reduction of the device output
to allow ventricular ejection and phasic aortic valve opening which must be echocardiogra‐
phycally assessed, since the degree of the outflow graft pulsatility alone do not predict the
presence of systolic aortic valve opening [41].
2.4.1.4. Deairing
Intraoperative echocardiography is very useful for detection of micro- or macro-bubbles and
result fundamental to direct de-airing of the heart after VAD implantion.
VADs components can contain significant amounts of air and, in adjunct, pulsatile devices
using negative filling pressures may drag air from the thoracic cavity into the circulation
especially at the inflow cannula insertion site resulting in the passage of air bubbles to the heart
and systemic circulation. The most common locations to which air will migrate, once CPB is
interrupted and pulmonary perfusion re-established, are the right coronary artery and the
innominate artery possibly contributing to ventricular dysfunction and/or neurologic injury.
Careful deairing should be performed before aortic cross clamp removal and before the pump
is set fully operational. Structures to be inspected include heart chambers and both ascending
and descending aorta using different TEE views (ME aortic valve long-axis view, ME ascend‐
ing aorta long-axis view and descending aorta short- and long-axis view).
2.5. Recovery and weaning
Identification of the ideal candidates for successful LVAD or RVAD weaning is still an open
topic and object of current study. The decision about possibility of successful weaning depends
on integration of clinical, hemodynamic and echocardiographic factors [42,43] as documented
by several studies reporting recovery and weaning protocols based on cardiopulmonary
testing, hemodynamic and echocardiographic variables [44].
The largest reports of weaning and removal from chronic LVAD support suggest as parameters
indicative of myocardial recovery a left ventricular ejection fraction ≥40% and a left ventricular
end diastolic diameter (LVEDD) inferior to 55-60mm [45]. Other echocardiographic variables
indicative of left myocardial recovery may be considered the fractional area change > 40%, and
the improved ventricular contractility.
Serial echocardiographic examination of the aortic valve opening movements, LVEF and
diameters at every reduction step of support is essential to evaluate a possible weaning,
because they will reflect the LV response to the progressive increase of preload and, thus, its
actual recovery.
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Invasive hemodynamic monitoring during dobutamine stress echocardiography has been also
proposed as a clinical test to assess the response of the assisted ventricle to unloading and
consider a possible weaning from assistance [46]. The improvement of cardiac index, LVEF in
absence of increased LVEDD and pulmonary capillary wedge pressure ≤ 15 mm are considered
favourable for successful device explantation.
The most important parameters to be evaluated and considered for weaning from RVAD
assistance are the right ventricular function, the central venous pressure, the degree tricuspid
regurgitation and the resulting left ventricular filling.
However, the evaluation and management of pulmonary vascular resistances (PVR) is the
most crucial issue when trying to wean patients from RVAD assistance. Because the success
of the procedure is actually strictly dependent by PVR optimization[47] when fixed PVR are
present patients will need supplementary management before attempting the weaning.
Echocardiographic and hemodynamic monitoring demonstrating left and right heart sections
maintaining a good function while decreasing the pump assistance without elevation of the
central venous pressure, and PVR indicate the possibility to successfully wean the patient from
the RVAD support.
Echocardiography evaluation of PVR can be performed by using the following formula :
PVR = ( VmaxTR / VTIRVOT ) + 0.16. (PVR are expressed in Wood units; VmaxTR= maximal tricuspid
regurgitation velocity; VTIRVOT = systolic velocity time integral of the RV outflow tract).
2.6. Echocardiography for systemic blood flow assessment
Echocardiography allows measurement of CO using standard two-dimensional imaging or,
more commonly, Doppler-based methods.
Doppler-based methods apply the following principle: if an ultrasound beam is directed along
the aorta using a probe, part of the ultrasound signal will be reflected back by the moving red
blood cells at a different frequency. The resultant Doppler shift in the frequency can be used
to calculate the flow velocity and volume and hence CO. In patients on MCS, LVAD- and
RVAD-CO can be separately assessed with a simple procedure [48].
Left and right ventricular outflow tract velocity-time integrals (VTIs) can be obtained by pulse
wave Doppler signals and used to estimate both the left and right stroke volume (SV) and
cardiac output (CO). For reliable measurements care must be taken to ensure an optimal angle
between the blood flow and Doppler beam. Once obtained the two (right and left) estimations
of cardiac output the following formula is used to have an indirect measure of the VAD output:
LVAD CO = (RVOT CO) – (LVOT CO).
A direct measurement of the VAD output can be also obtained using both the cross-sectional
area and pulse wave Doppler derived VTI in the outflow graft. For such calculation, as
previously mentioned, is necessary that the outflow graft blood flow and the Doppler beam
are maintained aligned and parallel as much as possible. Is usually advisable to use both the
direct and indirect method for CO estimations and verify their correlation because possible
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discrepancies can derive from incorrect probe alignment as well as overestimations of the
graft’s cross-sectional area, or the LVOT and RVOT diameters [41].
2.6.1. Echocardiography: Advantages and disadvantages
Echo-Doppler  has  the  key  advantage  of  providing  additional  variables  in  addition  to
blood  flow  as  previously  described.  The  main  disadvantage  of  Echo-Doppler  evalua‐
tion  is  that  it  is  operator  dependent  and  continuous  measurement  of  CO  using  this
technique  is  not  possible.  Moreover,  Echo-Doppler  evaluation  may  be  applied  either
trans-thoracically  or  trans-esophageally,  but  the  former  does  not  always  yields  good
images.  On the other  hand,  trans-esophageal  technique is  more invasive and is  uncom‐
fortable  in  non-intubated patients.
Echo-Doppler  CO  estimates  require  a  certain  expertise,  so  that  blood  flow  measure‐
ments  may  vary  considerably  due  to  the  difficulty  in  assessment  of  the  velocity  time
integral,  calculation  error  due  to  the  angle  of  insonation,  and  problems  with  correct
measurement  of  the  cross-sectional  area.  Conversely,  smaller  trans-esophageal  Doppler
probes  than  for  standard  esophageal  echocardiography  techniques  may  be  inserted
nasally.  They are operator-independent,  less  invasive and better  tolerated.  However these
probes focus on blood flow into the descending thoracic  aorta,  thus a  reliable  measure‐
ment  of  the  total  CO could  not  be  provided [49].  (See  Table  1  for  the  main  advantag‐
es  and disadvantages of  echocardiography).
3. Thermodilution methods to assess cardiac output
The determination of cardiac output (CO) during MCS is crucial, as low-output syndrome is
the main cause of death in such patients [15]. Several methods are available for blood flow
estimation and CO monitoring. However, the hemodynamic changes subsequent to VAD
implantation somehow limit the application of current methods for CO determination [50].
Two principal methods capable of assessing systemic blood flow are available in clinical
practice: thermodilution (ThD) and transpulmonary ThD system.
3.1. Pulmonary thermodilution method
The  techniques  based  on  pulmonary  ThD method employ  a  pulmonary  artery  catheter
(PAC) to monitor  CO. The intermittent  ThD technique employs a bolus of  ice-cold fluid,
which is  injected into  the  right  atrium via  a  PAC.  The change in  temperature  detected
in  the  blood  of  the  pulmonary  artery  is  used  to  calculate  CO.  This  technique  is  still
widely  considered  as  the  standard  method  in  clinical  practice  and  it  is  taken  as  the
reference  approach  when  comparing  new  CO  monitoring  technologies  [51].  More
recently,  PAC  has  been  adapted  to  incorporate  a  thermal  filament  (Vigilance™,  Ed‐
wards  Life  Sciences,  Irvine,  CA,  USA)  or  thermal  coil  (OptiQ™,  ICU  Medical,  San
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Clemente,  CA, USA) that  warms blood in the superior  vena cava and measures changes
in  blood  temperature  at  the  PAC  tip  using  a  thermistor  [52].  These  modified  techni‐
ques  provide  continuous  monitoring  of  systemic  blood  flow  (continuous  ThD-CO)  and
the displayed values represent  an average of  CO values over the previous 8-10 minutes.
3.2. Transpulmonary thermodilution method
The techniques based on transpulmonary thermodilution method allow CO to be assessed less
invasively, using a central venous (to allow injection of the indicator) and an arterial catheter,
rather than needing to introduce a catheter into the pulmonary artery. Among these systems,
PiCCO (Pulsion Medical Systems, Munich, Germany), and LiDCO (LiDCO Ltd, London, UK)
are the most widely used devices, which apply the same basic principles of dilution to monitor
blood flow as with PAC thermodilution [53].
PiCCO  uses  injections  of  cold  intravenous  fluid  as  the  indicator,  measuring  change  in
temperature  downstream  to  estimate  systemic  blood  flow  [54].  LiDCO  uses  small
amounts  of  lithium  chloride  as  the  indicator  and  measures  levels  using  a  lithium-
selective electrode [55].
3.3. Pulmonary and transpulmonary thermodilution method: Advantages and
disadvantages
The PAC has  a  key advantage  over  other  systems in  that  it  provides  measurements  of
other  hemodynamic parameters  in addition to systemic blood flow,  including pulmona‐
ry artery pressures,  right-sided and left-sided filling pressures,  and mixed venous oxygen
saturation (SvO2).  Moreover,  the PiCCO system provides variables  in addition to blood
flow, such as global  end-diastolic  volume and measurements of  extravascular lung water.
All  the  aforementioned  parameters  are  of  importance  in  patients  on  MCS  in  order  to
improve  treatment  of  pulmonary  hypertension,  avoid  fluid  overloading,  hypo-oxygena‐
tion,  and high oxygen consumption [18].
Another  main  advantage  of  continuous  ThD-CO  is  that  it  eliminates  variability  in  CO
estimates  in  the  presence  of  arrhythmias.  However,  it  has  the  disadvantage  of  not
displaying real-time values,  thus limiting its  usefulness for  assessing abrupt hemodynam‐
ic  changes in patients  with hemodynamic instability  [48].
Methods based on “cold” pulmonary ThD (bolus ThD), as well as systems for continuous “hot”
ThD (continuous ThD-CO) are theoretically suitable in patients assisted with a left VAD
(LVAD) but are unreliable techniques for patients on RVAD due to “cold or hot” indicator loss
bypassed by the pump from the right heart sections [56]. Similar limitations exist for systems
based on transpulmonary ThD, which cannot be applied to any patient on MCS [RVAD, LVAD
or biventricular assist devices (BiVAD)] unless modified set-up are used for application during
isolated RVAD, as indicator loss would happen in both the right and left heart sections [50].
However, the ThD techniques measure the right heart CO, which is conditioned by the
systemic venous return and by “total” left CO. Thus, they could actually provide the true
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systemic blood flow in patients on LVAD [56]. (See Table 1 for the main advantages and
disadvantages of thermodilution methods).
Assessment of: Echocardiography Thermodilution (PAC) Pulse ContourMethods
- Left ventricular function + - +
- Right ventricular function + + -
- Anatomical features + - -
- Cardiac output + + +
- Systemic arterial pressure - - +
- Pulmonary arterial pressure + + -
- Systemic vascular resistances - + +
- Pulmonary vascular resistances + + -
- Preload + + +/-
- Blood flow generated by VAD + - +/-
- Cardiac valve function + - -
- VAD components + - -
- Mixed venous oxygen saturation - + -
- Extravascular lung water - - +/-
General requirements of an “ideal” tool
- Accuracy + + +/-
- Reproducibility + + +
- Fast response time - - +
- Operator independency - - +
- Easy to use - + +
- Continuous use - +/- +
- Cost effectiveness - + +/-
- Minimally invasive + - +/-
- Clear data display and interpretation + + +
- Neonates to adults + - +/-
- Information that is able to guide
therapy + + +
+ satisfactory; - not satisfactory; +/- only some tools. PAC, pulmonary artery catheter.VAD, ventricular assist device.
Table 1. Main desirable characteristics of a monitoring tool to be used in patients on mechanical circulatory assistance
(see text for details).
4. Pulse contour methods to estimate systemic blood flow
The analysis of the arterial trace is the key point of the so called “pulse contour methods”
(PCMs). These techniques are based on the main assumption that the pressure rise during
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systole is related to the systolic filling of the aorta and proximal large arteries [57]. Thus, stroke
volume, and hence CO, can be derived by means of the analysis of the shape of the arterial
trace and the area under the pressure curve [58]. These are low-invasive techniques and allow
beat-by-beat CO determinations. Indeed, these systems provide a fast response time and may
represent suitable tools in patients on MCS, in whom sudden hemodynamic changes may lead
to hypotension and low output syndrome.
There are presently four major PCMs that are able to calculate CO and other cardiovascular
parameters from the analysis of the arterial pressure waveform: 1) PiCCO Monitor (Pulsion
Medical Systems, Munich, Germany), 2) LiDCO System (LiDCO Ltd, London, UK), 3) Vigileo
Monitor (Edwards Lifesciences LLC, Irvine, CA), and 4) MostCare Monitor (Vygon Health,
Padua, Italy) [54].
The PiCCO needs transpulmonary thermodilution for its calibration (i.e., iced bolus in a central
venous line) and a catheter into the femoral artery for the analysis of the arterial trace [59]. The
LiDCO system measures systemic blood flow after an external calibration with an intravenous
(centrally or peripherally) bolus of lithium [60]. The Vigileo system does not need external
calibration with a bolus but it requires internal calibration (i.e., patient demographic and
physical characteristics) for arterial impedance estimation [61]. The MostCare monitor has the
innovative feature of not necessitating external or internal calibration, being based on PRAM
(Pressure Recording Analytical Method) algorithm. Indeed, PRAM analyses the shape of the
arterial trace taking into account all the points of the pressure wave. Simultaneously, it relates
these points to the systolic and diastolic area under the pressure wave to estimate the interac‐
tion of left ventricle contraction with aortic impedance and compliance changes [62].
4.1. Pulse contour methods: Some practical considerations
Methods based on external calibration (i.e., bolus injected into a central or peripheral line) are
unreliable techniques for patients on RVAD due to indicator loss bypassed by the VAD from
the right heart sections [48]. Actually, these PCMs cannot be applied to any patient on MCS
(RVAD, LVAD or biventricular assist devices (BiVAD)) as their external calibration is affected
by indicator loss in both the right and left heart sections [63].
In order to avoid these limitations, PiCCO has been used in a patient on RVAD (Levitronix‐
CentriMag, Levitronix GmbH, Zurich, Switzerland) with a modified set-up for calibrating the
system. Basically, the investigators positioned a left atrial catheter to inject the iced solution,
instead of using a central venous catheter for the iced bolus [64]. However, this modified set-
up cannot be used in clinical practise because it is very invasive and highly risky.
A modified set-up of lithium bolus dilution was used for the calibration of LiDCO in patients
supported by a centrifugal pump (LevitronixCentriMag, Levitronix GmbH, Zurich, Switzer‐
land) in the RVAD configuration (between the right atrium and pulmonary artery). Indeed,
just before lithium bolus administration to the central venous catheter, the investigators
increased the RVAD’s revolutions per minute (RPM) as much as possible to ensure that all the
blood flowed through the RVAD and to avoid RVAD suction events. The increase in RPM
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before calibration caused streamlined blood flow from the right atrium to the RVAD, excluding
blood leakage through the native right ventricle [65].
MostCare has been recently used in 12 patients implanted with a pulsatile left ventricular assist
device (LVAD) (HeartMate-I XVE, HM-I, Thoratec Corporation, Pleasanton, CA, USA) [48]
and in one patient undergoing left (Jarvik 2000 axial flow pump, Jarvik Heart, Inc., New York,
NY) and right (Levitronix CentriMag, Levitronix GmbH, Zurich, Switzerland) ventricular
assist device implant [66]. Good performance with MostCare in such patients was found.
Moreover, there was no need for changing the set-up of the device, as it is the only PCM that
does not need external/internal calibration [66].
4.2. Pulse contour methods: Advantages, limitations and drawbacks in pulsatile and non-
pulsatile VAD
Incomplete LV unloading during mechanical circulatory support can occur as the result of
inadvertent and transient changes in afterload and preload (e.g. heart–lung interactions in
patients who are mechanically ventilated). As a consequence, the native heart can unpredict‐
ably open the aortic valve and eject a variable amount of blood into the ascending aorta [48].
Moreover, when a pulsatile LVAD is set to operate in fixed-rate mode, independently of
patient’s heart rate, such a discrepancy can itself determine the occurrence of residual effective
LV contractions and stroke outputs that can contribute to “total” CO (blood flow generated
by the LVAD plus stroke volumes produced by the native heart). Thus, depending on the
patient’s heart rate and the device’s stroke rate, arterial blood pressure waves related to
ventricular ejection may coincide with LVAD arterial pulse waves (being unapparent) or may
be variably interposed between the LVAD arterial pulse waves (Figure 1) [63].
A main advantage of  PCMs is  that  they compute systemic blood flow from the analysis
of  a  peripheral  artery.  Therefore,  their  blood  flow  estimation  could  represent  the  true
systemic  perfusion  (i.e.,  the  sum  of  the  contributions  from  the  native  left  ventricle
ejecting through the aortic  valve,  and the pump ejecting directly into the aorta)  [63].
A major  limitation  of  PCMs resides  in  the  fact  that  an  arterial  pulsatile  pressure  wave
(i.e.,  pulse  pressure)  must  be  present  for  CO estimation.  Thus,  some issues  about  their
reliability  exist  for  non-pulsatile  VADs,  where  incomplete  LV unloading  must  occur  to
generate  a  pulse  pressure  sufficient  to  allow  PCMs  to  compute  CO.  Conversely,  with
pulsatile  VADs  an  arterial  pulsatility  can  be  anyhow  detected,  independently  of
ventricular  loading  or  unloading  conditions.  In  such  conditions,  uncalibrated  PCMs
should be able to analyse the arterial  pressure wave morphology in any condition of  LV
preload [16].
With respect  to pulsatile  pump flow, rotary continuous-flow VADs produce less  pulsatile
and  non-physiologic  flows,  and  their  hemodynamic  characteristics  are  different  from
pulsatile  VADs.  First,  at  a  given  speed  rotation,  the  flow  through  a  rotary  device  is
variable,  generally  unquantifiable  and  it  is  sensitive  to  the  pressure  gradient  across  it
(aortic  minus  left  ventricular  pressure).  Secondly,  if  the  pump  speed  is  too  fast,  the
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arterial  pressure waveform decreases and the dicrotic  notch is  absent  (indicating a closed
aortic  valve).  Finally,  with a rotary VAD, the fluctuations in left  ventricular  pressure are
transmitted  to  the  systemic  arteries  through  the  device  even  when  the  pump  speed  is
sufficiently  high  to  maintain  the  closure  of  the  aortic  valve.  This  may  have  important
clinical  consequences  (e.g.  aortic  valve  cusp  fusion  and  thrombosis  in  the  ascending
aorta)  [67].  PCMs  could  be  useful  under  these  circumstances,  as  PCMs  analyse  pulsa‐
tile  flows  and  cannot  work  without  a  minimum  pulse  pressure.  Indeed,  a  “no-value”
alarm  on  the  screen  could  serve  as  a  “wake-up  call”  for  an  in-depth  hemodynamic
evaluation.  This  is  particularly true for  MostCare,  which displays the dicrotic  notch (and
hence the aortic  valve closure)  at  each cardiac cycle  [68].
Figure 1. The figure 1 shows the arterial wave recording of a patient under pulsatile left ventricular assist device (LVAD) by
the pulse contour method MostCare-PRAM (Pressure Recording Analytical Method). Values on y-axis are arterial pres‐
sures (mmHg). On x-axis are the cardiac cycles over time. The yellow vertical lines represent the identification of the dicrot‐
ic notch at each cardiac cycle. The arterial pressure waves are generated by LVAD stroke outputs. Of note, some smaller
pressure waves are interposed between them. These smaller arterial traces represent residual left ventricular ejections of
blood from the native heart. MostCare calculates the actual systemic total blood flow from the analysis of the sum of both
the waves (i.e., stroke volumes produced by the artificial plus the native ventricle) (see text for details).
A major advantage of PCMs is that they can provide information on fluid responsiveness and
cardiac function. In particular, MostCare is able to measure dP/dt (an index of myocardial
contractility) and cardiac cycle efficiency (CCE, an index of ventricular-arterial coupling). Both
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these indices may have importance in the assessment of cardiovascular performance during
the weaning from a VAD.
However, several factors could affect the accuracy of blood flow measurements and hemody‐
namic evaluation based on the analysis of the arterial waveform, such as arterial pathology in
the proximal segments, vasoplegic patients on vasoconstrictor therapy. Indeed, all these
conditions may affect the transmission of the pressure wave. Moreover, damped arterial
waveforms and inadequate pulse detection (e.g., catheter dislodgement) may influence the
precision of the pressure wave analysis [54,57,69,70]. (See Table 1 for the main advantages and
disadvantages of pulse contour methods).
5. Conclusions
The development of mechanical circulatory support technology is now moving from displace‐
ment pumps (pulsatile flow) to axial and centrifugal pumps (continuous flow). Hemodynamic
evaluation and measurement of blood flow is of crucial importance in patients on mechanical
circulatory support.
Echocardiography has emerged as an important tool to assess hemodynamic performance in
patients assisted with a ventricular assist device. However, it is operator dependent and cannot
be used as a continuous bedside monitoring device. On the other hand, other hemodynamic
monitoring techniques provide information on cardiac function and systemic blood flow on a
beat-by-beat basis. Unfortunately, many of them they have the limitation of not being appli‐
cable in some circumstances.
An ideal hemodynamic monitoring system should comprise all the key factors listed in Table
1. However, such a system does not currently exist so we must try and choose devices that
have a maximum of these attributes, bearing in mind that there is no “one size fits all” type of
system and one should, therefore, select the system most appropriate for each patient and for
each type of problem [54]. This is particularly true for patients supported with mechanical
circulatory support, in whom abrupt hemodynamic changes may lead to severe arterial
hypotension and clinical instability, which, in turn, are responsible for low output syndrome
and poor outcome.
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